Strides Pharma Science in its consolidated financial results for the quarter Q3FY25 ended December 31, 2024 reported revenues of Rs. 1,153.7 crore with a growth 14.6% YoY in Q3FY25. The PAT stood at ...

Strides Pharma Science Ltd (BOM:532531) reports a robust quarter with 13.3% revenue growth and significant debt reduction, while navigating challenges in regulated markets.

Revenue increased 15% YoY at ₹1,153.7 crore from ₹1,005.8 crore in Q3 FY24, marking a consistent business growth.

Arun Kumar, Founder and Executive Chairperson of the Company, has served in various positions on the Board of Strides since its inception. His current appointment as Executive Director is expiring on ...

Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger.